Published on 02/12/2025

Case Library: Data Readiness Wins and Fails

In the realm of pharmaceutical development, the integration of AI and machine learning (ML) into Good Automated Manufacturing Practice (GxP) analytics has become increasingly vital. The validation of these models, specifically in terms of data readiness, intended use, and bias, is crucial for regulatory compliance. The purpose of this guide is to provide a detailed step-by-step tutorial on the nuances of AI/ML model validation, including the aspects of intended use, data readiness curation, bias and fairness testing, model verification and validation, and the importance of explainability in AI (XAI). This structured approach will follow regulatory frameworks set by the US FDA, EMA, MHRA, and PIC/S.

Step 1: Understanding Intended Use in AI/ML Models

Intended use refers to the specific objectives for which an AI/ML model is designed and deployed. This concept is critical in ensuring that the application of AI/ML technologies aligns with regulatory expectations and is relevant to achieving predefined outcomes without compromising patient safety or data integrity.

To establish clarity on intended use, follow these steps:

• Define the Scope: Clearly articulate the specific clinical or operational objectives. For instance, will the AI/ML model be used for patient diagnosis, predictive analytics, or operational efficiency?
• Regulatory Considerations: Identify relevant regulatory guidance documents that relate to the model’s intended use, such as FDA’s AI/ML Software Guidance, which outlines essential expectations for software used in healthcare.
• Audience Definition: Understand who will utilize the AI/ML model – clinicians, data scientists, or regulatory bodies. Each stakeholder group may have different perceptions of intended use.
• Documentation: Create comprehensive documentation that delineates the intended use and expected outcomes. This should include any limitations associated with the AI/ML model.

By meticulously defining the intended use, organizations can streamline the validation process and preemptively address potential regulatory hurdles, thereby aligning current practices with expectations from agencies such as the FDA, EMA, or MHRA.

Step 2: Data Readiness Curation

Data readiness is the foundation upon which AI/ML models are built. It encompasses the collection, transformation, and validation of data to ensure that it is suitable for training and validating machine learning models. Proper curation is essential to establish the credibility of the AI/ML outputs.

To effectively curate data for your AI/ML models, consider the following steps:

• Data Collection: Gather data from multiple sources, ensuring that it represents the population intended for analysis. This may include electronic health records, clinical trial data, or real-world evidence.
• Data Quality Assessment: Conduct thorough assessments of data quality, focusing on accuracy, completeness, timeliness, and consistency. Any omissions or errors can lead to significant derogatory impacts on model performance.
• Data Transformation: Preprocess the data through cleaning, normalization, and transformation. This ensures that the dataset is suitable for the AI/ML modeling process without introducing bias.
• Bias Identification: Implement statistical methods and techniques to identify and quantify potential biases in the dataset. This is vital for building an unbiased model.

Data readiness curation is a critical step, as inadequate data can lead to model failures and associated regulatory non-compliance. Regulatory bodies often scrutinize data readiness during audits, especially under guidelines such as GAMP 5, which specifies good practices in software development and management.

Step 3: Bias and Fairness Testing

Bias in AI/ML models is not merely an ethical concern; it poses real-world risks that can affect patient outcomes and lead to regulatory implications. Bias and fairness testing must be integral components of AI/ML model validation.

Adopting the following approach may help ensure that your model is thoroughly tested for bias:

• Define Bias Types: Understand the types of bias that may exist, including selection bias, measurement bias, and algorithmic bias, and how they could specifically affect the AI/ML model.
• Testing Framework: Develop a framework for assessing bias through model evaluation. This may include stratified evaluations to ensure performance parity across various demographics.
• Fairness Metrics: Select appropriate fairness metrics, such as demographic parity or equal opportunity rates, to evaluate how the model performs across different population segments.
• Iterative Processes: Implement iterative testing cycles to continually refine and improve the model. This includes post-deployment monitoring to assess how the model performs over time.

By embedding bias and fairness testing into the model validation lifecycle, organizations can build greater trust in AI/ML outputs and mitigate risks associated with adverse outcomes stemming from biased data.

Step 4: Model Verification and Validation

Verification and validation (V&V) constitute the cornerstone of establishing the reliability and compliance of AI/ML models in pharmaceutical contexts. V&V processes ensure that the model meets its design specifications and performs effectively within specified limits.

The following steps outline a comprehensive approach to model V&V:

• Verification Process: Assess whether the model was built according to specifications. This includes validating every component of the model, from data preprocessing to algorithm implementation.
• Validation Process: Conduct testing against predefined criteria using separate datasets. This serves to ensure that model predictions align with clinical or operational objectives.
• Performance Metrics: Establish clear performance metrics to evaluate model output, such as accuracy, precision, recall, F1 score, and area under the receiver operator characteristic curve (AUC-ROC).
• Documentation: Maintain detailed documentation throughout the V&V process, ensuring traceability and auditability. This is particularly important under constructs like 21 CFR Part 11, which governs electronic records and signatures.

Completing a rigorous V&V process helps fulfill regulatory requirements, enhances model credibility, and minimizes risks associated with model deployment in critical pharmaceutical applications.

Step 5: Explainability in AI (XAI)

Explainability in AI (XAI) is becoming increasingly essential, especially in pharmaceutical applications where decision-making impacts patient care and regulatory compliance. The ability to elucidate model decisions reassures users and regulatory agencies alike.

Implement the following strategies to enhance the explainability of your AI/ML models:

• Choose Interpretable Models: Whenever possible, select inherently interpretable models, such as decision trees or linear regression, which provide clearer insights into decision-making processes.
• Utilize Explainability Tools: Leverage visualization tools and techniques like SHAP (SHapley Additive exPlanations), LIME (Local Interpretable Model-Agnostic Explanations), or partial dependence plots to visualize model decisions.
• Stakeholder Engagement: Involve multiple stakeholders, including clinicians and regulatory affairs professionals, in the development of interpretability strategies. Their insights can guide the explainability efforts in a meaningful direction.
• Documentation of Explainability: Ensure that all explanations are documented clearly and made accessible for audit trails. This supports compliance with regulatory requirements regarding transparency.

The evolving focus on explainability addresses not only ethical considerations but also regulatory demands, reinforcing the integrity of pharmaceutical AI/ML initiatives.

Step 6: Drift Monitoring and Re-validation

Once AI/ML models are implemented, they must be monitored regularly to ensure consistent performance over time. Drift—where the performance of the model degrades or changes due to shifting data distributions—poses a significant risk in dynamic pharmaceutical environments.

The following steps outline an effective drift monitoring and re-validation process:

• Continuous Monitoring: Implement systems to monitor the performance of AI/ML models continuously, tracking metrics that might indicate model drift.
• Define Drift Thresholds: Establish thresholds for acceptable changes in model performance metrics. This pre-emptive measure can trigger alerts for required interventions.
• Scheduled Re-validation: Designate a schedule for periodic re-validation of machine learning models using up-to-date data sets, ensuring the model remains relevant and compliant with current regulatory standards.
• Documentation of Changes: Maintain a comprehensive record of all monitoring and re-validation activities. This documentation provides essential audit trails that demonstrate ongoing compliance and proactive risk management.

By deploying monitor-and-revalidate strategies, pharmaceutical organizations can enhance the reliability and safety of their AI/ML systems, contributing positively to patient care and organizational integrity.

Conclusion

The integration of AI/ML into GxP analytics necessitates a robust validation framework addressing intended use, data readiness, bias, and overall compliance. By systematically applying the steps outlined in this guide, organizations can ensure regulatory adherence while optimizing their AI/ML validation approaches. Continuous commitment to the principles of validation, explainability, and ethical standards is crucial in navigating the complexities of modern pharmaceutical environments.